Slides
Page 1
Investor Presentation Q1FY26 25-07-2025 1
Page 2
DISCLAIMER Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, fluctuation in earnings, foreign exchange rates, our ability to manage international operations and exports, our exposure to market risks as well as other risks. The investor presentation is not intended to endorse, advertise, promote or recommend the use of any products listed in it which are for representation purpose only, some of which are reference listed drugs of which the Company has approved, under approval or under development generic equivalents. The prefixes “g” and “generic” used interchangeably indicate the generic versions of the named brand drugs. Information relating to any medical products or medical devices contained herein is provided by Cipla for general information purposes only. Information on any of the medical products or medical devices may vary from country-to-country. A reference to a medical product or a medical device does not imply that such medical product or medical device is available in your country. The commercial availability of the medical products or medical devices listed herein in your country is dependent on the validity and status of existing patents and/or marketing authorizations related to each. An independent enquiry regarding the availability of each medical products or medical device should be made for each individual country. The product information contained herein is not intended to provide complete medical information, and is not intended to be used as an alternative to consulting with qualified doctors or health care professionals. Nothing contained herein should be construed as giving of advice or the making of a recommendation and it should not be relied on as the basis for any decision or action. It is important to only rely on the advice of a healthcare professional. 2
Page 3
Profitability Momentum Continues with Strong EBITDA Margin at 25.6% 1. Market data as per IQVIA week ended 20th Jun 2025 | 2. Market data as per IQVIA MAT May’25 Business Performance Snapshot Revenue EBITDA PAT INR 6,957 Cr 4% (YoY) INR 1,778 Cr 4% INR 1,298 Cr 10% $ 226 MnINR 3,070 Cr 11%$ 102 Mn $ 101 Mn 8% Successfully launched Voltido Trio, our flagship addition to the Respiratory portfolio Albuterol ranked #1 in the overall U.S. Albuterol MDI market1 with a market share of 19.5% SA private Growing at a market multiple2 of 1.5x Solid growth driven by portfolio leverage Q1FY26 (YoY) (YoY) One India North America One Africa Emerging Markets & Europe Q1FY26 25.6% of Revenue 18.7% of Revenue (YoY) (YoY) 3 6% (YoY)
Page 4
Financial Performance – Q1FY26 Revenue1 Break-up One India, 44% North America, 28% One Africa, 13% Emerging Markets & Europe, 12% API, 1% Others, 2% Revenues INR 6,957 Cr EBITDA INR 1,778 Cr Actuals (INR Cr) vs Q1 FY25 Total Revenue from Operations 6,957 3.9% EBITDA 1,778 3.6% EBITDA % 25.6% -7 bps PAT 1,298 10.2% PAT % 18.7% 106 bps Q1FY26 (Consolidated) R&D2 1. India includes Rx + Gx + CHL; One Africa includes South Africa, North Africa, Sub -Saharan Africa and Cipla Global Access| 2. Opex including depreciation | 3. Total debt includes lease liabilities and working capital loan| 4. Cash Balance includes current investments, fixed deposits, margin deposits and excluding unclaimed dividend balances | 5. Net Cash is Cash balance, net of Total Debts 6.2% of revenue 4 Balance Sheet Strength Jun-25 Total Debt3 Cash Balance4 Net Cash5 INR 459 Cr INR 10,838 Cr INR 10,379 Cr INR 432 Cr
Page 5
Branded Prescription ❖ Cipla maintained #2 market2 rank in overall Chronic with a Chronic mix of 61.5% ❖ Key therapies like - Respiratory, Urology, Anti-diabetes, Cardiac and Anti-infectives outpaced the market2 growth ❖ The Voltido Trio range is gaining significant market traction Trade Generics ❖ Business delivered a strong growth during the quarter ❖ 2 Brands with TTM revenue of > INR 100 Cr and 5 Brands with TTM revenue of INR 50 Cr to INR 100 Cr ❖ 7 new launches in Q1 FY26, including entry into Orthopaedics to expand therapy coverage Consumer Health ❖ Delivered a robust growth with anchor & transitioned brands continuing to grow bigger ❖ Sustained EBITDA trajectory ❖ Nicotex3, Omnigel4 and Cipladine4 ranked #1 in the market One India1 - Committed to Sustainable Progress and Enduring Impact 1. India includes Branded Prescription, Trade Generics and Consumer Health| 2. Market data as per IQVIA MAT Jun’25| 3. Market data as per IQVIA Apr’25 | 4. Market data as per AC Neilsen Apr’25 5 Highest ever Q1 Sales Q1FY26 Revenue One India revenue trend Crossed the threshold INR 3,000+ Cr for the first time ever in the opening quarter of any financial year INR 3,070 Cr
Page 6
India Rx - Strengthening Our Journey with Strategic Therapeutic Focus 1. Market data as per IQVIA MAT Jun’25 | 2. Market data as per IQVIA MAT Jun’23 23 Brands IPM1 Brands in Top 300 ranks Key Market Highlights IPM1 Brands with revenue > INR 100 Cr Steady uptake in key therapies1 growth (%) 6 Therapies With IPM1 Top 5 ranks 29 Brands #1 Foracort Biggest Brand in IPM1 6 Largest pharma company by volume (units) in market1 5 brands added in the category of market1 revenue > INR 100 Cr YoY Cipla’s Respiratory supremacy, with its brands occupying all top 6 spots in IPM1 29 Brands 13% 9% 19% 8% 6% 12% 8% 13% 5% 5% Cardiac Anti-diabetes Urology Anti-infectives Respiratory Market Growth Cipla Growth (13%)2 (16%)2 (12%)2 (13%)2 Slow industry growth in Respiratory and Anti-infectives
Page 7
CLICK TO EDIT MASTER TITLE STYLE One India : Accelerating Innovative Portfolio in Respiratory and Other Chronic Therapies Respiratory Strategic Restructuring in Respiratory: Dedicated Team Set Up to Drive Triple Launches ❑ Foracort G Inhaler: India’s first triple therapy (Glycopyrrolate + Formoterol + Budesonide) for enhanced COPD control ❑ Voltido Trio Inhaler: Advanced triple combo (Fluticasone Furoate + Umeclidinium + Vilanterol) for improved lung function ❑ Glycohale FB Inhaler: World’s first DPI triple drug (Formoterol + Budesonide + Glycopyrronium) for comprehensive COPD care 7 Other Chronic Therapies ❑ Launched Empa and achieved 4th rank amongst new players post LOE launch ❑ Strengthened presence through acquisition of 2 brands in neuropathic pain & sleep disorder ❑ Launched XTIKTR (1st of its kind in Asia), a minimally invasive treatment for urethral strictures Anti-Diabetes CNS Urology
Page 8
8 Q1 FY26 - Global Consumer Wellness Franchise INR 141C`r Skin Infection Pain Relief Cold & Cough Nicotine Replacement Hydration Cold &Cough Pain Management Respi OTC Cold & Cough One India One Africa Consumer brands in One India Revenue: INR 470 Cr Consumer brands in South Africa Revenue: ZAR 358 Mn 2 2 2 2 1 1. Market ranks as per IQVIA Apr’25 | 2. Market ranks as per AC Neilsen Apr’25 | Above numbers exclude sales of wellness brands through prescription channel Respi OTC
Page 9
North America - Witnessed Continuous Traction in Key Differentiated Assets • Albuterol ranked No. 1 in the market1 (50 million+ inhaler units supplied to the U.S. market cumulatively) • Lanreotide market2 share increased to 21% during the quarter • Launched key assets Nano Paclitaxel (ANDA) and Nilotinib (NDA), strengthening our oncology portfolio • Signed agreement to launch first biosimilar product for Cipla in the US, launch expected in Q2 FY26 Key Business Highlights 1. Market data as per IQVIA week ended 20th Jun 2025 (No. 1 rank in overall U.S. Albuterol MDI market) | 2. Market data as per IQVIA MAT May’25 9 Key Product launches Nano Paclitaxel - 100 mg/vial (ANDA) Nilotinib Capsules - 50, 150 and 200 mg (NDA) Pipeline Update • Respiratory - gAdvair closer to commercialization; preparing for gSymbicort, and a couple of inhalation assets launch in FY27 • The business remain committed to launching 2–3 peptide assets in FY26
Page 10
ANDA & NDA Portfolio & Pipeline (As on 30th Jun 2025) 1. PEPFAR approved ANDAs can be commercialised in U.S. 178 Approved ANDAs & NDAs 39 Tentatively Approved ANDAs & NDAs 65 Under Approval ANDAs & NDAs 282 Total ANDAs & NDAs 1 10 94 14 44 9 22 4 66 1 15 9 2 2 Approved ANDAs & NDAs Tentatively Approved ANDAs & NDAs Under Approval ANDAs & NDAs Cipla Ltd PEPFAR Invagen Partnered ANDAs/NDAs
Page 11
Market Segment2 Rank Share Cipla Growth Market Growth South Africa Prescription 2 8.8% 6.8% 4.8% South Africa OTC 3 8.5% 3.3% 1.8% South Africa Overall 3 8.7% 5.6% 3.8% One Africa1 - South Africa Private Growing 1.5x Faster than the Market 1. One Africa - South Africa, North Africa, Sub-Saharan Africa (SSA) and Cipla Global Access (CGA) | 2. Market data as per IQVIA MAT May’25 In the prescription market2 SA Ranked #2 Across multiple therapies in Q1 FY26 5 new launches SA Key Highlights2 9 brands with MAT market revenue > 100 Mn ZAR Healthy performance across key therapies like Respiratory, CNS and Anti-infectives SA Private Revenue trend $ Mn ZAR Mn Highest number of brands in top 30 (7), top 50 (12) and top 100 (20) within generics segment 11 939 1,044 1,063 Q1FY24 Q1FY25 Q1FY26 56 59 19 23 8 9 8 12 Q1FY25 Q1FY26 SA Private SA Tender North Africa Others (SSA & CGA)
Page 12
12 12 Q1FY25 Q1FY26 Revenue 93 101 Q1FY25 Q1FY26 Revenue Q1FY26 - Emerging Markets & Europe and API Emerging Markets & Europe API $ Mn $ Mn 12
Page 13
CLICK TO EDIT MASTER TITLE STYLE Progress on ESG Goals (India Manufacturing Operations) - FY25 13 Goals (India manufacturing operations) Progress as on 31st March 2025 80% reduction in absolute Scope 1 (energy based) and Scope 2 emissions* 58% reduction from the baseline year, FY 2019-20 Water neutrality Achieved 1.75 times water positive Zero Waste to Landfill (‘ZWTL’) All Cipla India Manufacturing operations are ZWTL certified 50% renewable electricity 64% renewable electricity Continuing zero fatality in our manufacturing operations Two fatalities in FY 2024-25 Full compliance with safe discharge targets established by AMR Industry Alliance Achieved full compliance with the safe discharge targets ➢ Suppliers audited on ESG accounted for ~36% of the total procurement expenditure ➢ Completed desk-based assessments for 186 vendors and 50 on-site assessments AMR Certification Ciprofloxacin & Azithromycin made at Indore and Goa plant respectively are Anti Microbial Resistance (‘AMR’) compliant, certified by BSI. Other Highlights ➢ 67% of India manufacturing operations are Zero Liquid Discharge ('ZLD’) sites ➢ Cipla is one of the Indian pharmaceutical companies to conduct and publish a report on Double Materiality Assessment. *Cipla undertook a strategic reassessment of emissions goals and has revised the target from carbon neutral to emission reduction Supplier ESG Assessment Other HighlightsAMR Certification
Page 14
Consolidated Profit and Loss Note : Figures have been rounded-off INR Cr 14 Particulars Q1 FY26 Q1 FY25 Revenue from sale of products 6,837 6,625 Other operating income 120 69 Income from operations 6,957 6,694 Material cost 2,171 2,193 Employee benefits expense 1,312 1,194 Other expenses 1,696 1,591 Total expenses 5,179 4,978 Finance costs 14 18 Depreciation, impairment and amortization expense 253 247 Other income 259 160 Profit before exceptional items and tax 1,770 1,611 Exceptional Items - - Profit beforetax 1,770 1,611 Tax expenses 478 435 Share of associate -0 -1 Profit for the period 1,292 1,175 Non-controlling interest -6 -2 Profit for the period attributable to shareholders 1,298 1,178
Page 15
Consolidated Balance Sheet #Total debt includes lease liabilities and working capital loan | * Cash & cash equivalents includes current investments, fixed deposits, margin deposits and excluding unclaimed dividend balances |Figures have been rounded-off INR Cr 15 Key Balance Sheet Items Jun-25 Jun-24 Equity 32,665 28,058 Total Debt# 459 547 Inventory 6,091 5,531 Cash and Cash Equivalents* 10,838 8,996 Trade Receivables 6,254 4,989 Trade Payables 3,093 2,742 Net Tangible Assets 6,669 6,210 Goodwill and Intangibles 5,138 4,941
Page 16
Thank You Registered Office : Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013 For any queries, please contact Diksha Maheshwari Investor.Relations@cipla.com For more information please visit www.cipla.com 16